Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-national, multi-center, DB [double-blind], placebo-controlled, parallel group, fixed dose efficacy and safety study of SR58611A [amibegron] 350 mg twice daily vs. placebo in adults with major depressive disorder on concomitant treatment with escitalopram 10mg/d.

Next Previous
Trial Profile

A multi-national, multi-center, DB [double-blind], placebo-controlled, parallel group, fixed dose efficacy and safety study of SR58611A [amibegron] 350 mg twice daily vs. placebo in adults with major depressive disorder on concomitant treatment with escitalopram 10mg/d.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amibegron (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms ALBERIO

Most Recent Events

  • 02 Dec 2008 Actual patient number (510) added as reported by ClinicalTrials.gov.
  • 02 Dec 2008 Actual start date changed from Feb 2007 to Jan 2007 as reported by ClinicalTrials.gov.
  • 02 Dec 2008 Additional trial identifier EudraCT2006-004146-16 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top